Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab plus weekly paclitaxel in platinum‑resistant or refractory relapsed ovarian cancer
2008-005449-43Phase 2Terminated
- Sponsor
- Morphotek
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing Paclitaxel + farletuzumab with Paclitaxel + placebo (2 arms). Primary endpoint: Progression-free survival. Started Apr 2009; status: terminated.
02
Drugs
farletuzumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2008-005449-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005449-43.